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Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is 
an inherited arrhythmogenic disease that can cause syncope or sud-
den cardiac death during emotional or physical stress in the abs-
ence of detectable structural heart disease and a prolonged QT in-
terval on an electrocardiogram (ECG). Mutations in two genes, the 
cardiac ryanodine receptor gene (RyR2) and calsequestrin 2 gene 
(CASQ2), have been identified in patients with CPVT. These mutations 
lead to an increase in intracellular Ca
++ concentration, resulting in life-
threatening ventricular arrhythmias, possibly via delayed depolariz-
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A 16-year-old male with a prior history of recurrent syncope was referred to our hospital after being resuscitated from cardiac arrest de-
veloped while playing volleyball. His electrocardiogram (ECG) demonstrated ventricular fibrillation at a local emergency department. After 
referral, an ECG showed bidirectional ventricular tachycardia (VT) and nonsustained Torsade de Pointes. Two days later, his heart rate be-
came regular, and no additional episodes of VT were observed. His ECG showed sinus rhythm with a corrected QT interval of 423 msec, and 
two-dimensional echocardiography was unremarkable. We made the diagnosis of a catecholaminergic polymorphic VT. However, only pre-
mature ventricular complex bigeminy was induced on exercise ECG and epinephrine infusion tests, and the patient showed no episodes of 
syncope. His father and mother had different missense mutations in the cardiac ryanodine receptor on genetic testing. The proband had 
both mutations in different alleles and was symptomatic. It was recommended that the patient avoid competitive physical activities, and a 
β-blocker was prescribed. (Korean Circ J 2012;42:129-132)
KEY WORDS: Catecholamines; Tachycardia, ventricular; Genetics; Syncope; Exercise.
Received: June 15, 2011
Revision Received: July 3, 2011
Accepted: July 4, 2011
Correspondence: Yongkeun Cho, MD, Department of Internal Medicine, 
Kyungpook National University School of Medicine, 130 Dongdeok-ro, Jung-
gu, Daegu 700-721, Korea
Tel: 82-53-420-5528, Fax: 82-53-426-2046
E-mail: choyk@mail.knu.ac.kr
• The authors have no financial conflicts of interest.
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work 
is properly cited.
ations. Molecular genetic testing for RYR2 and CASQ2 is clinically 
available. Here, we report a case of CPVT with the identified genetic 
mutations.
Case 
A 16-year-old male, who had suffered from recurrent episodes of 
syncope triggered by physical exertion was referred to our hospital 
after undergoing defibrillation at a local emergency department (ED). 
He had lost consciousness at school during a volleyball test that was 
also emotionally stressful. Paramedics found him pulseless and st-
arted cardiopulmonary resuscitation. An initial ECG at a local ED re-
vealed ventricular fibrillation. Although his arrhythmia was convert-
ed to sinus rhythm after defibrillation, the patient was stuporous 
and had repeated episodes of nonsustained ventricular tachycardia 
(VT). After referral to our hospital, ECG monitoring in the ED and in-
tensive care unit showed intermittent nonsustained VT and bidi-
rectional VT (Fig. 1). When the patient became agitated, his heart 
rate increased, and the ECG showed nonsustained polymorphic VT 
despite intravenous administration of a β-blocker. He was sedated 
and placed on mechanical ventilation. Two days later, his heart rate 
was regular, and no additional episodes of VT were observed. Seda-
tion was stopped, and the patient was weaned from the ventilator. 130  Catecholaminergic Polymorphic Ventricular Tachycardia With Recurrent Exertional Syncope
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His ECG showed a sinus rhythm with a corrected QT interval of 423 
msec (Fig. 2). Routine laboratory findings, including electrolytes and 
two-dimensional echocardiography, were unremarkable. A detailed 
history of the patient included several episodes of syncope since the 
age of 8 years associated with physical activities, such as sprinting, 
playing football, and fighting with a sibling. His father also experienc-
ed an episode of syncope associated with sprinting at the age of 9 
years. No other family members had histories of syncope or sudden 
cardiac death. The patient and his family underwent a genetic analy-
sis, and his father and mother each had one different de novo mis-
sense mutation in RyR2 (exon 97 c.14009T>A p.L4670H in the father 
and exon 37 c.5428G>C p.V1810L in the mother). The symptomatic 
proband inherited both mutations. As his episodes of syncope were 
associated with sympathetic activation, an exercise ECG test and 
epinephrine infusion test (intravenous bolus of 0.1 μg/kg followed 
by continuous infusion at rates of 0.1 μg/kg per minute) were per-
formed. However, only premature ventricular complex (PVC) bige-
miny was induced with no episodes of syncope during the exercise 
ECG test (Fig. 3) and epinephrine only increased his heart rate with-
out an arrhythmia. With these clinical features, we made the diag-
nosis of CPVT. Atenolol (37.5 mg bid; 1.9 mg/kg/day) was prescribed, 
and a follow-up exercise ECG test while on the β-blocker was per-
formed 3 days later. During the follow-up exercise ECG test, fewer 
PVCs were seen at peak exercise. The patient remains on 50 mg bid 
atenolol (2.3 mg/kg/day) and is being followed. To date, he has been 
free of episodes of syncope.
Discussion
Catecholaminergic polymorphic ventricular tachycardia, arrhy-
thmogenic right ventricular cardiomyopathy, and long QT syndrome 
are well known causes of exercise-induced syncope that commonly 
manifest normal baseline ECGs.
1)2) Therefore, many provocation tests, 
including VT induction, an exercise ECG test, and epinephrine infu-
Fig. 1. Twelve-lead electrocardiogram in the coronary care unit shows bidirectional ventricular tachycardia.
Fig. 2. Baseline electrocardiogram shows a normal sinus rhythm with a normal QT interval.131 Na Young Kim, et al.
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sion tests, have been used to diagnose exercise-induced syncope.
1)2) 
Exercise-induced bidirectional VT has been considered the hallmark 
of CPVT for many years. However, recent studies
1)2) have shown that 
ventricular bigeminy is the most common exercise-induced arrhy-
thmia among patients with CPVT, and serious arrhythmias such as 
bidirectional VT and polymorphic VT are rarely induced. Therefore, 
exercise-induced ventricular bigeminy no longer should be consider-
ed an innocent arrhythmia, at least in suspicious cases of CPVT. Th-
erefore, exercise ECG testing for diagnosing CPVT may be suboptimal.
Catecholaminergic polymorphic ventricular tachycardia may have 
both an autosomal dominant and an autosomal recessive pattern of 
inheritance. The more common type 1 autosomal dominant CPVT is 
caused by mutations in RyR2 on chromosome 1q42-q42 and results 
from defective calcium release from the sarcoplasmic reticulum, 
which is required for myocardial contraction.
3) A mutation in RyR2 
can increase calcium release and cause life-threatening ventricular 
arrhythmias. Patients with RYR2 mutations become symptomatic at 
an early age, and men are at higher risk for cardiac events.
4) In the 
autosomal recessive variant, type 2 CPVT, the causative gene is CASQ2, 
located on chromosome 1p13-21.
5) CASQ2 encodes calsequestrin, a 
calcium buffering protein in the sarcoplasmic reticulum, which binds 
a large amount of calcium. While the mechanism by which this mut-
ation causes ventricular arrhythmias has not been clearly establish-
ed, the mutated protein may be associated with the following: loss 
of polymerization of CASQ monomers, loss of calcium buffering ca-
pability, or indirect destabilization of the ryanodine receptor channel.
6)7)
Patients with CPVT, in which many forms of exercise are associat-
ed with catecholamine release that triggers VT, should be cautioned 
against virtually all forms of vigorous and/or competitive physical 
activity.
8) Since the early reports on CPVT, β-blockers have been used 
as primary therapy for CPVT,
9)10) and they are indicated for both ch-
ronic treatment and acute therapy for sustained VT. Other antiar-
rhythmic drugs such as amiodarone and class I drugs have proved 
to be ineffective.
11) However, these issues were addressed in a study 
that evaluated both the molecular mechanisms and clinical effica-
cy of flecainide in mice and humans.
12) Implantable cardioverter de-
fibrillators can be considered for primary prevention despite the 
potential drawbacks in young patients and concerns about provok-
ing arrhythmic storms. Left cardiac sympathetic denervation has 
been reported effective in patients whose symptoms were not ad-
equately controlled by β-blockers.
13) This approach may also be con-
sidered for individuals with intractable arrhythmic storms to reduce 
the number of implantable cardioverter-defibrillator shocks.
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